The Influencing Factors of 12 Week Efficacy of Polyethylene Glycol Losenatide in Type 2 Diabetes Patients

Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Nov 3, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a medication called polyethylene glycol Losenatide to see how well it works for people with type 2 diabetes over a 12-week period. Researchers want to understand how this treatment affects various aspects such as body fat, insulin resistance (how well your body uses insulin), weight, blood sugar levels, and even stomach size. By gathering information on these factors, the trial aims to provide better evidence for diabetes treatment that can help improve patients' health.

To participate in this study, candidates need to be diagnosed with type 2 diabetes and have certain health conditions, such as a body mass index (BMI) over 24 and an HbA1c level of at least 7.5%, which indicates how well their blood sugar has been controlled over time. Participants should also be willing to maintain a healthy diet and exercise routine during the trial. Those who have recently used specific diabetes medications or have certain health issues may not qualify. If you join the study, you can expect regular monitoring and support as researchers assess how well the treatment works for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Type 2 diabetes was diagnosed according to World Health Organization(WHO) classification or other locally applicable diagnostic criteria.
• • At least 8 weeks of simple diet control and physical exercise before screening; Type 2 diabetes patients with stable hypoglycemic drug treatment and insufficient blood glucose control within 8 weeks before screening.
• • HbA1c≥7.5%.
• • Body mass index (BMI) \> 24kg /m2.
• • Subjects agreed to maintain scientific diet and exercise habits throughout the study, regularly conduct self blood glucose monitoring (SMBG) and make records.
• • Willing to sign the written informed consent and abide by the research protocol.
• Exclusion Criteria:
• • Any of the following drugs or treatments were used within one year before screening: GLP-1RA, GLP-1 analogues, DPP-4 inhibitors or any other incretin analogues.
• • Long term (more than 7 consecutive days) intravenous administration, oral administration and intra-articular administration of corticosteroids received within 2 months prior to visit 1.
• • Used drugs with weight control effect or performed surgery that may lead to unstable weight within 2 months before screening, or is currently in the weight loss plan and not in the maintenance stage.
• • History of acute and chronic pancreatitis; History of myeloid C-cell carcinoma, MEN 2A or 2B syndrome, or related family history.
• • Clinically significant abnormal gastric emptying.
• • Any organ system tumors that have been treated or not treated within 5 years prior to visit 1.
• • Have received coronary angioplasty, coronary stent implantation, and coronary artery bypass surgery within 6 months prior to visit 1, and have experienced negligent compensatory heart failure (NYHA class III and IV of New York Heart Association), stroke or transient ischemic attack, unstable angina, myocardial infarction, and persistent and clinically significant arrhythmia.
• • Acute metabolic complications occurred within 6 months prior to visit 1.
• • Before screening, any laboratory test index meets the following standards: glutamic pyruvic transaminase\>2.5 times or glutamic oxaloacetic transaminase\>2.5 times; eGFR\<45ml\\/min\\/1.73m2； Fasting triglyceride\>5.64mmol /L.